GPCM
ALLO icon

Granite Point Capital Management’s Allogene Therapeutics ALLO Stock Holding History

Granite Point Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-100,000
Closed -$1.49M – 127
2021
Q4 		$1.49M Buy
+100,000
New +$1.76M 0.25% 73

Other funds holding ALLO

TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Granite Point Capital Management's ALLO Position: Q1 2022 in Review

Granite Point Capital Management sold out of Allogene Therapeutics (ALLO) in Q1 2022, closing a stake of 100,000 shares — an estimated $1.49M sold.

Granite Point Capital Management first reported a position in ALLO in Q4 2021 and held it in 1 quarter. The position peaked at $1.49M in Q4 2021. 180 funds tracked by Wall St. Rank hold ALLO as of Q1 2022.

  • Granite Point Capital Management reported no remaining Allogene Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Granite Point Capital Management sold 100,000 Allogene Therapeutics shares in Q1 2022, an estimated $1.49M.
  • Granite Point Capital Management first reported a position in Allogene Therapeutics in Q4 2021 and held it in 1 quarter.
  • Granite Point Capital Management's Allogene Therapeutics position peaked at $1.49M in Q4 2021.
  • 180 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2022.

Based on Granite Point Capital Management's 13F filing for Q1 2022, filed 11 May 2022.